๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia : Review of three randomized trials

โœ Scribed by Wolfgang Kern; Elihu H. Estey

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
400 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of acute nonlymphocytic leukem
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside
โœ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 362 KB ๐Ÿ‘ 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
โœ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 447 KB ๐Ÿ‘ 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete

High doses of cytosine arabinoside (HD-A
High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia
โœ Zittoun, R. ;Marie, J. P. ;Pommier, Y. ;Pochat, L. ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB ๐Ÿ‘ 1 views

High doses of Cytosine-arabinoside (Ara-C) (1 to 3gm/mz every 12 hours during 48 hours) were administered monthly to 5 acute myeloid leukemia patinets during complete remissions subsequent to relapses and reinduction treatment. Plasma Ara-C was measured using a radioimmunoassay and exhibited kinetic